Bank of America/Merrill Lynch analyst Douglas Becker downgraded oil service company Core Laboratories (CLB) to Underperform from Buy today, arguing that much of the stock’s recent strength is due to short covering. • Becker writes that Core Labs is now trading at 24 times forward earnings, above the high end of its traditional trading range. And the stock’s momentum could slow as a program to settle warrants goes away.
“Since May CLB has entered four accelerated programs to settle roughly 6.6 million warrants originally scheduled to settle over a 20 day period ending in Jan. 2012. We believe shares have been shorted against these warrants, resulting in short covering when the warrants are settled, driving volume – and arguably the shares – higher.”